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Abstract (261 words) 
Background: The aim of this study was to evaluate the contribution of alcohol-use disorder 
to hepatitis C virus (HCV)-related decompensated cirrhosis diagnosis in three settings. 
Methods: HCV notifications from British Columbia (BC), Canada, New South Wales 
(NSW), Australia, and Scotland (1995-2011/2012/2013, respectively) were linked to hospital 
admissions (2001-2012/2013/2014, respectively). Alcohol-use disorder was defined by non-
liver-related hospitalisation due to alcohol use. Age-standardised decompensated cirrhosis 
incidence rates were plotted, associated factors were assessed using Cox regression, and 
alcohol-use disorder-associated population attributable fractions (PAFs) were computed. 
Findings: Among 58,487, 84,529, and 31,924 people with HCV in BC, NSW, and Scotland, 
2,689 (4.6%), 3,169 (3.7%), and 1,375 (4.3%) had a decompensated cirrhosis diagnosis, and 
28%, 32%, and 50% of those with decompensated cirrhosis had alcohol-use disorder, 
respectively. Age-standardised decompensated cirrhosis incidence rates were considerably 
higher among people with alcohol-use disorder in NSW and Scotland. Decompensated 
cirrhosis was independently associated with alcohol-use disorder in BC, aHR 1.92, 95% CI 
1.76, 2.10; NSW, aHR 3.68, 95% CI 3.38, 4.00, and; Scotland, aHR 3.88, 95% CI 3.42, 4.40. 
The PAFs of decompensated cirrhosis-related to alcohol-use disorder were 13%, 25%, and 
40% in BC, NSW, and Scotland, respectively. Interpretation: Alcohol-use disorder was a 
major contributor to HCV liver disease burden in all settings, more distinctly in Scotland. The 
extent to which alcohol use would compromise the individual and population level benefits of 
direct-acting antiviral therapy (DAA) needs to be closely monitored. Countries, where 
appropriate, must develop strategies combining DAA treatment uptake promotion and 
alcohol-use disorder management, if World Health Organization 2030 HCV mortality 





The burden of advanced liver disease has been rising among people with hepatitis C globally.  
The prospect of increased access to direct-acting antiviral (DAA) therapies instigated the 
World Health Organization (WHO) to set ambitious targets for elimination of hepatitis C as a 
major public health threat by 2030. However, continued heavy alcohol intake is likely to 
impact potential benefits of DAA-based cure on individual-level liver disease progression 
and population-level liver disease burden.  The aim of this study was to evaluate the 
contribution of alcohol-use disorder to hepatitis C-related decompensated cirrhosis diagnosis 
in British Columbia, Canada, New South Wales, Australia, and Scotland. Alcohol-use 
disorder was a major contributor to hepatitis C-related liver disease burden in all settings, 
more distinctly in Scotland. The extent to which alcohol use would compromise the 
individual and population level benefits of DAA-based therapies needs to be closely 
monitored. Countries, where appropriate, must develop strategies combining DAA treatment 
uptake promotion and alcohol-use disorder management, if WHO 2030 hepatitis C mortality 




The burden of advanced liver disease has been rising among people with hepatitis C virus 
(HCV) infection globally [1]. The prospect of increased access to direct-acting antiviral 
(DAA) therapies instigated the World Health Organization (WHO) to set ambitious targets 
for elimination of hepatitis C as a major public health threat by 2030 [2]. However, in settings 
with higher levels of alcohol-use disorder (AUD), the potential for HCV treatment programs 
to achieve the WHO liver mortality reduction target of 65% could be compromised, without 
developing concurrent strategies to reduce the consumption and impact of alcohol.   
 
Action against AUD is particularly important given that people with HCV infection are more 
likely to engage in harmful consumption [3], and alcohol is a risk factor for higher liver-
related mortality [4]. However, given the limited number of population-based studies, the 
relative contribution of AUD to the burden of liver disease in different HCV populations is 
not clear. The WHO HCV elimination strategy has highlighted the need to address alcohol 
use as a common co-morbidity among people with HCV infection [2]; yet, reducing the 
impact of alcohol is not included among target areas. Restriction of access to DAA treatment 
on the basis of ongoing alcohol use is present in many settings [5, 6], further potentially 
impacting treatment programs in WHO regions with higher per capita alcohol consumption 
[7]. 
 
Globally, British Columbia (BC), Canada, New South Wales (NSW), Australia, and Scotland 
are among the few settings with established surveillance systems that enable monitoring 
people with HCV infection, by linkage between HCV diagnosis databases and hospitalisation 
records. The aim of this study was to evaluate the contribution of AUD to population level 
decompensated cirrhosis (DC) diagnosis among people with an HCV notification.  
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Materials and methods 
Data sources and record linkages  
BC, Canada 
The British Columbia Hepatitis Testers Cohort (BC-HTC) holds records of all individuals 
tested for HCV, HBV, and HIV at the BC Centre for Disease Control Public Health 
Laboratory, since 1992, or reported as a confirmed case of HCV, HBV, and HIV/AIDS, since 
1990.[8] At the end of each episode of admission, all BC hospitals submit their 
hospitalisation records (including demographic, administrative, and diagnosis information) 
directly to the Canadian Institute of Health Information for inclusion in the Discharge 
Abstracts Database, since 1985 [9]. All hospitalisation records are coded using the 10
th
 
revision of the Classification of Diseases and Related Health Problems (ICD-10), since 2001. 
Information on all deaths registered in BC are held by the BC Vital Statistics Agency, since 
1985 [10]. Using personal health numbers assigned to each individual in BC, BC-HTC 
records were deterministically linked to hospitalisation and mortality datasets. Record 




The NSW Notifiable Conditions Information Management System (NCIMS) holds records of 
all individual with positive HCV and HBV serology tests, notified of diagnoses via 
mandatory notification procedures, since 1991 [11]. National HIV Registry holds records of 
all notifications of HIV infection, since 1985 [12]. NSW Admitted Patient Data Collection 
covers all inpatient admissions from all hospitals in NSW, since 2001 [11]. Each 
hospitalisation record includes demographic, administrative and diagnosis information coded 
at discharge according to ICD-10 [11]. Information on all deaths registered in NSW are held 
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by the Registry of Births, Deaths and Marriages, since 1993 [11]. Using demographic details 
(including full name, gender, date of birth, and address), probabilistic linkages of records 
between the NCIMS, hospitalisation, and mortality datasets were undertaken by the NSW 
Centre for Health Record Linkage [11]. 
 
Scotland 
Health Protection Scotland holds records of all individuals with positive HCV and HBV 
serology tests since 1991 and 1998, respectively [13]. Notifications of HIV diagnosis have 
been recorded since 1981 [13]. Hospital admission data are available from the Scottish 
Morbidity Records, comprising all Scottish hospitalisations since 1981, including 
demographic, administrative and diagnosis information coded at the end of each episode of 
admission (according to ICD-10 since 1996) [13]. Information on all deaths registered in 
Scotland are held by the National Records of Scotland, since 1980 [14]. Using unique 
identifiers and demographic details (including forename initial, surname Soundex, gender, 
date of birth, and postcode district of residence), a combination of deterministic and 
probabilistic linkages of records between the HCV notifications, hospitalisation, and 
mortality datasets were undertaken by Information Services Division Scotland [13]. 
 
Study period 
In BC, NSW, and Scotland, HCV notifications were extracted for the study period between 1 
January 1995 and 31 December 2011, 2012, and 2013, respectively, and; linked 
hospitalisation records were extracted for the study period between 1 January 2001 and 31 
December 2012, 2013, and 2014, respectively. In each setting, linked mortality records were 





The primary outcome of interest was first-time hospitalisation due to DC. A hospital 
discharge diagnosis code (ICD-10) was used to infer diagnosis of DC; coded in either the 
principal or secondary diagnosis fields of a linked inpatient hospital record. The set of 
relevant codes included: ascites (R18), bleeding oesophageal varices (I85.0 and I98.3), 
chronic hepatic failure (including hepatic encephalopathy) (K72.1 and K72.9), alcoholic 
hepatic failure (K70.4), and hepatorenal syndrome (K76.7). Hereafter, a first-time DC 
hospital admission is referred to as DC diagnosis.  
 
Exclusion criteria 
Exclusion criteria were applied as follows: records where date of birth was missing, and 
records where the date of HCV notification occurred more than three months after date of 
death (post-mortem notification), or prior to January 1, 1995. 
 
Statistical analysis 
Among people with an HCV notification in each setting, trends in DC diagnosis numbers and 
age at DC diagnosis were evaluated. Age-standardised DC incidence rates [per 100 person-
years (PY)], and corresponding 95% CIs were calculated assuming a Poisson distribution, 
overall and stratified by AUD. The European Standard Population 2013 was used for 
standardisation. The strength of association between risk factors and DC diagnosis was 
assessed using unadjusted and adjusted Cox proportional hazard regression analyses; 
covariates included birth cohort, gender, year of HCV notification, HBV and HIV co-
infection, and AUD. The population attributable fractions (PAFs) and 95% CIs of DC 
diagnosis associated with AUD were computed based on the adjusted regression analyses, 
overall and stratified by birth in or after 1965 [15].   
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AUD is a standard term used to define continued drinking despite adverse mental and 
physical consequences [16]. Liver-related consequences of alcohol use are not included in the 
definition of AUD [16]. A hospital discharge diagnosis code (ICD-10) at any point prior to 
DC diagnosis was used to infer the presence of AUD; coded in either the principal or a 
secondary diagnosis field of a linked inpatient hospital record. The set of relevant codes 
included: alcohol-induced Pseudo-Cushing's syndrome (E24.4), mental and behavioural 
disorders due to use of alcohol (F10), degeneration of nervous system due to alcohol (G31.2), 
alcoholic polyneuropathy (G62.1), alcoholic cardiomyopathy (I42.6), alcoholic myopathy 
(G72.1), alcohol rehabilitation (Z50.2), and alcohol abuse counselling and surveillance 
(Z71.4). Hereafter, having a history of at least one AUD-related hospital admission is referred 
to as AUD. AUD was not included as a time-dependent variable in Cox proportional 
regression analyses, given that it is considered to be an indicator of a long-standing condition. 
To calculate age-standardised DC incidence rates, assess factors associated with DC 
diagnosis, and evaluate PAFs, person-time at risk was defined to start six months post the 
date of HCV notification, and to end at whichever occurred first; death, or end of follow-up, 
assigned by year. Statistical analyses were carried out in STATA versions 12 and 13 or SAS 
version 9.4. 
 
Role of the funding source 
The funding sources did not have any role in study design, data collection and analysis, 
interpretation of data, writing of the report, and the decision to submit the paper for 
publication. The corresponding author had full access to all data in the study and had final 





Study participants  
There were 58,487 people with an HCV notification in BC, 84,529 in NSW, and 31,924 in 
Scotland (total n=174,940) during the study period. The BC population was older (70% born 
before 1965), compared to NSW (47%) and Scotland (28%). The proportion of people with 
AUD was highest in Scotland (27%), followed by BC (19%), and NSW (18%). There were 
2,689 (4.6%) people with a DC diagnosis in BC, 3,169 (3.7%) in NSW and 1,375 (4.3%) in 
Scotland. Across the three settings, those with a DC diagnosis were more likely to be born 
during 1945-1964 and male. The proportion of people with a DC diagnosis and AUD was 
highest in Scotland (50%), followed by NSW (32%), and BC (28%) (Table 1).  
 
Age at DC diagnosis 
The age distribution at DC diagnosis varied across settings, with median age of 54 years 
[interquartile range (IQR) 48, 60] in BC, 50 years (IQR 45, 56) in NSW, and 46 years (IQR 
39, 53) in Scotland. However, in all settings, compared to those without AUD, people with 
AUD had a younger age distribution, with median age of 52 vs. 56 years (P<0.001) at DC 
diagnosis in BC; 48 vs. 52 years (P<0.001) in NSW and; 43 vs. 49 years (P<0.001) in 
Scotland (Figure 1). 
 
DC diagnosis numbers and rates 
In BC, NSW, and Scotland, DC diagnosis numbers increased from 196, 192, and 68 in 2004 
to 295 in 2011 (P<0.001), 351 in 2012 (P<0.001), and 157 in 2013 (P<0.001), respectively. 
Among people with AUD in the three settings, DC diagnosis numbers increased from 52, 57, 
and 36 in 2004 to 88 in 2011 (P=0.025), 145 in 2012 (P=0.001), and 72 in 2013 (P=0.003), 
respectively. Since 2004, age-standardised DC incidence rates have remained relatively stable 
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in all settings, although consistently higher among those with AUD in NSW and Scotland 
(Figure 2). 
 
Factors associated with DC diagnosis 
In unadjusted analyses, factors associated with DC diagnosis were consistent across all three 
settings. DC diagnosis was associated with older age, male gender, more recent HCV 
notification years (≥2007), HIV and HBV/HIV co-infection, and AUD. In unadjusted 
analyses, HBV co-infection was associated with DC diagnosis in BC and NSW (Table 2). 
Similar demographic and clinical factors were associated with DC diagnosis in adjusted 
analyses (Table 3). The association between DC diagnosis and more recent HCV notification 
years was driven by older age (Supplementary Table 1). In adjusted analyses across the three 
settings, AUD independently predicted DC diagnosis [adjusted hazard ratio (aHR) BC 1.92, 
95% CI 1.76, 2.10; NSW 3.68, 95% CI 3.38, 4.00; and Scotland 3.88, 95% CI 3.42, 4.40] 
(Table 3).  
 
Contribution of alcohol dependency to DC diagnosis 
Overall, in BC, NSW, and Scotland, AUD was associated with a PAF of 13% (95% CI 11%, 
15%), 25% (95% CI 23%, 27%), and 40% (95% CI 36%, 44%) of DC diagnoses, 
respectively. Among people born in or after 1965 in BC, NSW, and Scotland AUD was 
associated with a PAF of 21% (95% CI 16%, 25%), 36% (95% CI 32%, 40%), and 48% 





This study outlines the rising absolute burden of HCV-related liver disease in BC, Canada; 
NSW, Australia; and Scotland. The increasing DC diagnosis numbers highlight the limited 
impact of interferon-containing HCV treatment programs across the three settings, as well as 
the combined effects of ageing and co-morbidities for liver disease progression. The impact 
of alcohol on liver disease progression among people with chronic HCV is evident through 
the younger age distribution of those with DC and AUD, and the higher attributable fractions 
for AUD among younger people with DC diagnosis. The overall contribution of AUD to DC 
diagnosis was highest in Scotland, the setting with the youngest age distribution, and lowest 
in BC, consistent with the older age demographic in this setting. Elimination of HCV 
infection as a public health threat by 2030 is defined by a 65% reduction in liver-related 
mortality and an 80% reduction in incidence compared with the 2015 baseline [2]. To reach 
the 65% mortality reduction component of the elimination target, concentrated policy action 
is required to enhance HCV treatment uptake, and where needed, improve AUD management 
at the national level. The availability of data on mandatory HCV notifications and the 
capacity for regular linkage to other administrative databases provides the opportunity for 
ongoing evaluation and comparison of HCV public health strategies in the DAA era between 
BC, NSW, and Scotland. 
 
Across the three settings, suboptimal efficacy and uptake of interferon-based therapies were 
among the major gaps in the HCV care cascade during the 2000s-early 2010s [1]. Over the 
coming decade, enhanced uptake of highly effective interferon-free DAA therapies is 
expected to significantly reduce the burden of HCV-related liver disease [17]; however, the 
impact of different strategies needs to be closely monitored. Australia has adopted a broad 
DAA access strategy without liver disease stage or drug and alcohol restrictions since March 
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2016. Disease staging has been required for access to new therapies in BC and Scotland in 
2016; however, eligibility criteria are opening to all disease stages as numbers of people with 
advanced liver disease diminish. Nonetheless, HCV-related liver disease is a multifactorial 
problem, to which antiviral therapy is only a partial solution [18]. The anticipated 
preventative impact of improved therapies has to be evaluated through linkage to individual-
level treatment data, across the three settings. Such comparison should be possible in the near 
future, following procedures to enable access to government-subsidised treatment datasets. 
 
The major contribution of AUD to DC diagnosis has important policy implications in all 
settings. Strong evidence exists for the effectiveness of several strategies to reduce harmful 
consumption at the population level, including those targeting the pricing, availability and 
marketing of alcohol [19]. Canada is among a handful of countries that has implemented and 
evaluated the impact of different forms of minimum alcohol pricing [20]. Increasing 
minimum prices in Canada have been shown to be associated with significant reductions in 
harmful patterns of use, and alcohol-related hospitalisation and mortality [21-23]. In most 
countries however, governments fail to follow the evidence on alcohol management policies, 
given lack of popular support and difficulties of implementation [19]. Intricate patterns of 
consumption and alcohol-related harm further complicate the application and evaluation of 
management policies. In Scotland, alcohol-related morbidity and mortality have declined in 
recent years; however, these declines are not consistently distributed among the population, 
with the greatest burden recorded among those living in the most deprived areas [24]. In 
Australia, overall levels of drinking have declined during the last decade; however, diverging 
drinking patterns indicate these declines are mostly concentrated among lighter drinkers, 
while the top ten percent of heavier drinkers are responsible for an increasing proportion of 
total consumption [25]. Despite these differences, in developing country-specific 
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management policies, tackling harmful consumption should remain integral to improving 
population level health outcomes and reducing social inequalities. After a prolonged battle 
with the well-organised and well-funded alcohol industry groups, Scotland has successfully 
passed legislation to introduce minimum unit pricing for alcohol. Ten years after 
implementation of this policy, the Scottish government estimates there would be at least 300 
fewer alcohol-related deaths and 6,500 fewer hospital admissions each year [24]. In 
Australia, debates about minimising alcohol-related harm have increased in recent years [26, 
27], instigating the Commonwealth government to explore the concept of a public interest 
case for minimum pricing of alcohol [28]. However, major alcohol policy reforms are yet to 
be implemented by the federal and state governments.  
 
Across the three settings, older age was the strongest predictor of DC diagnosis. The causal 
relationship between ageing and increased risk of HCV-related complications is likely 
explained by a combination of longer duration of infection and ageing-related impaired repair 
mechanisms [29]. People born prior to 1945 were particularly at higher risk of developing 
DC. Interestingly, a recent study has demonstrated major acceleration in the development of 
HCV-related cirrhosis after the age of 50, irrespective of duration of infection [29]. Other 
predictors of DC diagnosis included AUD, male gender, and HBV/HCV/HIV co-infection. 
These characteristics are among well-defined risk factors for faster liver disease progression 
[30]. Defining an individual’s risk of liver disease progression is often difficult, due to the 
non-linear nature of disease progression, and fluctuating lifestyle co-factors [31]. However, 
heavy alcohol use (>50 g/d) has been shown to be associated with end-stage liver disease 
diagnosis and liver-related mortality, independent of chronic HCV infection or viral 
eradication by therapy [32]. Given its significant impact, where needed, effects of AUD 
should be mitigated in order to lower the risk of liver disease progression among people with 
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HCV infection. Integration of alcohol dependency treatment in medical settings could 
optimise management of AUD and facilitate provision of treatment by multidisciplinary 
teams, including psychosocial interventions, pharmacological therapy, and medical 
management of AUD and liver disease [33].  
 
This study has several limitations. First, DC diagnosis was defined by a limited number of 
conditions that appear to be strong indicators of the decompensated stage of cirrhosis; 
however, this definition has not been validated against the clinical diagnoses of DC and 
requires further validation studies. Second, using administrative data for defining AUD has 
clear limitations.  In sensitivity analysis, across the three settings, 72-94% of people who had 
a first-time hospitalisation due to alcoholic liver failure also had a non-liver AUD-related 
admission; the majority of which (71-85%) were recorded before the first-time alcoholic liver 
failure hospitalisation. Further, a previous population-based study in Scotland has shown 
moderate and higher levels of self-reported alcohol consumption and binge drinking are 
major risk factors for subsequent alcohol-related hospitalisation (based on ICD codes) [34]. 
Finally, a validation study of administrative data (based on ICD codes) vs. chart notations has 
demonstrated 68% sensitivity and 97% specificity for the administrative data-based diagnosis 
of alcohol problem drinking [35]. Positive predictive value was 87%, and negative predictive 
value was 91%. Taken together, these findings suggest the current study has potential under-
ascertainment of AUD, with potential overestimation of the impact on DC risk if more severe 
forms of AUD were more likely to be classified. Third, to improve the accuracy of trends in 
DC diagnosis numbers and age-standardised rates across the settings, these data were 
displayed and analysed since 2004. In Scotland, the pre-2004 DC trends were overestimated, 
given low HCV diagnosis rates during the early-mid 2000s (62% undiagnosed in 2006) [36]. 
Fourth, in the analysis of the association between DC diagnosis and more recent HCV 
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notification years, this study could not evaluate the potential impact of HCV diagnosis among 
people with more advanced liver disease in recent years. Previous findings from BC and 
NSW suggested the number of individuals with a late HCV notification  has been declining in 
the 2000s (defined by an HCV notification before, at the time, or within two years before DC 
diagnosis); however, in the late 2000s, approximately 20% of people with HCV-related DC 
diagnosis still had a late HCV notification  [37, 38]. Fifth, other factors might have 
contributed to lower age-standardised DC rates in BC, including residual confounding 
(attributed by unmeasured co-morbidities), and the older age distribution in this setting 
compared to the standard population. Sixth, HCV diagnosis for surveillance reporting is 
generally based on anti-HCV antibody detection and does not require HCV RNA 
confirmation. Thus, an estimated 25% of HCV notifications would have undergone 
spontaneous HCV clearance. Finally, the impact of antiviral therapy on DC diagnosis has not 
been evaluated in this study. Nevertheless, a minority of people would have received HCV 
treatment during the study period. These limitations should not have a major impact on the 
study findings, given the surveillance definition and systems in the three settings have been 
stable throughout the study period.  
 
In conclusion, this international comparison of population level data provides evidence for 
the rising absolute burden of HCV-related advanced liver disease in BC, NSW, and Scotland, 
highlighting the combined impact of suboptimal HCV treatment efficacy and uptake, aging, 
and significant contribution of AUD to DC diagnosis. These findings suggest, where needed, 
action against AUD should form a strong component of HCV public health strategies. 
Continued heavy alcohol intake is likely to impact potential benefits of DAA-based cure on 
individual-level liver disease progression and population-level liver disease burden. Use of 
administrative databases for surveillance, particularly with the addition of individual-level 
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antiviral treatment data will be a valuable tool for ongoing evaluation and comparison of the 
impact of DAA-based therapies on the individual-level liver disease progression and 
population-level burden of HCV, given differences in the epidemiology of HCV and HCV 
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Table 1. Demographic characteristics among people with an HCV notification in BC, 
NSW, and Scotland, since 1995 
 
BC, Canada  
HCV notifications 
1995-2011 























Characteristics, n % n=58,487 % n=2,689 % n=84,529 % n=3,169 % n=31,924 % n=1,375 % 
Birth cohort 
          
  
    ≥1965 17,397 30 210 8 45,298 54 611 19 22,889 72 602 44 
    1945-1964 35,616 61 1,981 74 34,518 41 2,171 69 8,051 25 681 50 
    ≤1944 5,474 9 498 19 4,713 6 387 12 984 3 92 7 
Male 
β
 38,212 65 1,860 69 53,146 63 2,319 73 21,369 65 1,002 73 
Year of HCV 
notification           
  
     1995-2000 28,517 49 1,449 54 39,043 46 1,461 46 9,141 29 377 27 
     2001-2006 18,339 31 920 34 26,754 32 1,088 34 9,645 30 545 40 
     2007-2011/12/13 11,631 20 320 12 18,732 22 620 20 13,138 41 453 33 
Co-infection status             
    None 51, 381 88 2,241 83 80,112 95 2,934 93 30,653 96 1,289 94 
    HBV 3,255 6 229 9 3,467 4 184 6 587 2 41 3 
    HIV 2,910 5 150 6 888 1 45 1 645 2 40 3 





11,078 19 742 28 14,797 18 1,023 32 8,757 27 693 50 
α
DC diagnosis during 2001-2012 in BC, 2001-2013 in NSW, and 2001-2014 in Scotland, 
β
among people with 
available information, 
γ
among people with a DC diagnosis, Alcohol-use disorder was included if occurred prior 
to DC diagnosis 
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Table 2. Unadjusted analysis of factors associated with DC diagnosis among people with an HCV notification in BC, NSW, and 
Scotland, since 1995 
 
BC, Canada  
HCV notification, 1995-2011 
n=55,873 
NSW, Australia  
HCV notification, 1995-2012 
n=82,526 
Scotland  
HCV notification, 1995-2013 
n=30,746 
Characteristics, n % 
DCα 
n=2,443 
% HRβ 95% CI P 
DCα 
n=2,559 
% HRβ 95% CI P 
DCα 
n=1,020 
% HRβ 95% CI P 
Birth cohort       
  
        
    ≥1965 198 1 1.00 - - 479 1 1.00 - - 466 2 1.00 - - 
    1945-1964 1,804 5 4.21 3.64, 4.88 <0.001 1,750 5 4.59 6.81, 9.01 <0.001 490 7 2.97 2.61, 3.37 <0.001 
    ≤1944 441 10 9.18 7.77, 10.86 <0.001 330 8 7.83 4.15, 5.08 <0.001 64 8 4.45 3.43, 5.79 <0.001 
Gender      
    
      
    Female 749 4 1.00 - - 690 4 1.00 - - 287 3 1.00 - - 
    Male 1,694 5 1.24 1.14, 1.35 <0.001 1,860 4 1.63 1.50, 1.78 <0.001 732 4 1.28 1.11, 1.46 <0.001 
Year of HCV 
notification 
               
     1995-2000 1,443 5 1.00 - - 1,355 4 1.00 - - 274 4 1.00 - - 
     2001-2006 792 4 1.14 1.04, 1.25 0.003 879 3 1.11 1.01, 1.23 0.032 397 4 1.28 1.09, 1.51 0.002 
    ≥2007 208 2 1.31 1.12, 1.53 0.001 325 2 1.51 1.30, 1.75 <0.001 249 2 1.42 1.16, 1.75 0.001 
Co-infection status                
    None 2016 4 1.00 - - 2,387 3 1.00 - - 958 3 1.00 - - 
    HBV 214 7 1.60 1.39, 1.84 <0.001 132 4 1.35 1.13, 1.61 0.001 26 5 1.39 0.94, 2.05 0.100 
    HIV 144 5 1.32 1.12, 1.57 <0.001 36 4 1.66 1.20, 2.31 0.002 31 5 1.82 1.27, 2.60 0.001 
    HBV/HIV 69 8 2.01 1.58, 2.56 <0.001 4 7 3.57 1.34, 9.53 0.011 5 14 5.48 2.27, 13.19 <0.001 
Alcohol-use disorderγ         
  
      
      No 1,775 4 1.00 - - 1,672 2 1.00 - - 464 2 1.00 - - 
      Yes 668 7 1.82 1.67, 1.99 <0.001 887 6 2.96 2.73, 3.21 <0.001 556 7 3.62 3.20, 4.10 <0.001 
α
DC diagnosis during 2001-2012 in BC, 2001-2013 in NSW, and 2001-2014 in Scotland, 
β
 hazard ratio, 
γ
among people with a DC diagnosis, AUD was included if occurred 
prior to DC diagnosis 
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Table 3. Adjusted analysis of factors associated with DC diagnosis among people with an HCV notification in BC, NSW, and Scotland, 
since 1995 
 
BC, Canada  
HCV notification, 1995-2011 
n=55,873 
NSW, Australia  
HCV notification, 1995-2012 
n=82,526 
Scotland  
HCV notification, 1995-2013 
n=30,746 





















 95% CI P 
Birth cohort       
  
        
    ≥1965 198 1 1.00 - - 479 1 1.00 - - 466 2 1.00 - - 
    1945-1964 1,804 5 4.55 3.93, 5.28 <0.001 1,750 5 5.13 4.63, 5.69 <0.001 490 7 3.07 2.70, 3.49 <0.001 
    ≤1944 441 10 11.13 9.40, 13.19 <0.001 330 8 11.90 10.30, 13.75 <0.001 64 8 7.09 5.43, 9.25 <0.001 
Gender      
    
      
    Female 749 4 1.00 - - 690 4 1.00 - - 287 3 1.00 - - 
    Male 1,694 5 1.15 1.06, 1.26 0.001 1,860 4 1.43 1.31, 1.56 <0.001 732 4 1.15 1.00, 1.32 0.048 
Year of HCV 
notification 
  
   
          
     1995-2000 1,443 5 1.00 - - 1,355 4 1.00 - - 274 4 1.00 - - 
     2001-2006 792 4 1.36 1.24, 1.49 <0.001 879 3 1.25 1.13, 1.37 <0.001 397 4 1.46 1.24, 1.72 <0.001 
    ≥2007 208 2 1.81 1.55, 2.12 <0.001 325 2 1.87 1.61, 2.17 <0.001 249 2 1.81 1.48, 2.23 <0.001 
Co-infection status                
    None 2016 4 1.00 - - 2,387 3 1.00 - - 958 3 1.00 - - 
    HBV 214 7 1.55 1.35, 1.79 <0.001 132 4 1.40 1.17, 1.67 <0.001 26 5 1.34 0.94, 1.99 0.138 
    HIV 144 5 1.55 1.31, 1.84 <0.001 36 4 1.61 1.16, 2.24 0.005 31 5 1.50 1.04, 2.14 0.028 
    HBV/HIV 69 8 2.37 1.86, 3.02 <0.001 4 7 2.66 1.00, 7.10 0.051 5 14 5.50 2.28, 13.27 <0.001 
Alcohol-use disorder
γ
        
  
      
      No 1,775 4 1.00 - - 1,672 2 1.00 - - 464 2 1.00 - - 
      Yes 688 7 1.92 1.76, 2.10 <0.001 887 6 3.68 3.38, 4.00 <0.001 556 7 3.88 3.42, 4.40 <0.001 
α
DC diagnosis during 2001-2012 in BC, 2001-2013 in NSW, and 2001-2014 in Scotland, 
β
adjusted hazard ratio, 
γ
among people with a DC diagnosis, AUD was included if 




Table 4. Population attributable fraction of DC diagnosis associated with alcohol-use disorder among BC, NSW, and Scotland people 
with an HCV notification, since 1995 
 
BC HCV notification, 1995-2011 
n=55,879 
NSW HCV notification, 1995-2012 
n=82,526 
Scotland HCV notification, 1995-2013 
n=30,746 
















 95% CI 
All 688 7 13 11, 15 887 6 25 23, 27 556 7 40 36, 44 
Born ≥1965 90 3 21 16, 25 247 3 36 32, 40 309 5 48 43, 53 
Born <1965 598 9 12 10, 14 640 13 22 20, 24 247 12 33 28, 37 
α 




Figure 1. Age at DC diagnosis among people with an HCV notification in BC, NSW, and 





Figure 2. Temporal trends in DC diagnosis numbers and age-standardised incidence 
rates among people with an HCV notification in BC, NSW, and Scotland, by alcohol-use 
disorder, since 1995 
 
 
 
